Issue Date: July 24, 2006
Aptamers link Archemix, Elan
Archemix and Elan have joined forces to discover and develop aptamers, single-stranded nucleic acids whose binding behavior is similar to that of antibodies, for the treatment of autoimmune disease. Archemix snares a $7 million up-front payment from Elan and could receive more than $350 million in milestones and royalties. The companies will target IL-23, a cytokine that is a mediator in chronic autoimmune inflammatory diseases such as multiple sclerosis, Crohn's disease, psoriasis, and rheumatoid arthritis.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society